|
|
Volumn 345, Issue 23, 2001, Pages 1699-1700
|
|
Removing the primary tumor after the cancer has spread
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA2B INTERFERON;
INTERLEUKIN 2;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG INDUCED DISEASE;
DRUG RESPONSE;
EDITORIAL;
HUMAN;
KIDNEY TUMOR;
MAJOR CLINICAL STUDY;
META ANALYSIS;
METASTASIS;
MULTICENTER STUDY;
NEPHRECTOMY;
PATIENT SELECTION;
PRIORITY JOURNAL;
RANDOMIZATION;
RANDOMIZED CONTROLLED TRIAL;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
COMBINED MODALITY THERAPY;
HUMANS;
INTERFERON ALFA-2B;
INTERLEUKIN-2;
KIDNEY NEOPLASMS;
NEOPLASM METASTASIS;
NEPHRECTOMY;
PATIENT SELECTION;
PUBLICATION BIAS;
SURVIVAL ANALYSIS;
|
|
EID: 0035818916
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJM200112063452310 Document Type: Editorial |
|
Times cited : (13)
|
|
References (9)
|
